** Brokerage H.C. Wainwright starts coverage on cancer therapy maker ImmunityBio IBRX.O with "buy" rating and $8 PT; represents 161% upside to the stock's last close
** Brokerage says co is expected to see "compelling growth opportunity for 2025" in its bladder cancer therapy, Anktiva; estimates $4.3 bln in sales by 2034
** Believes Anktiva can be a "backbone therapy" with a wide range of applications, but its value is "highly underappreciated"
** Anktiva + BCG vaccine achieved the highest complete response rate, 62%, outperforming competitors like Merck's MRK.N Keytruda and Ferring's Adstiladrin - Brokerage
** Last month, FDA authorized co's new version of the BCG vaccine to treat bladder clancer
** IBRX fell ~51% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.